ライフサイエンスコーパス: mother-to-child transmission

1 to explaining the adverse effect of VA/BC on mother-to-child transmission.

2 HIV prevention, including the prevention of mother-to-child transmission.

3 have investigated the viral determinants of mother-to-child transmission.

4 dren exposed to nevirapine for prevention of mother-to-child transmission.

5 evolution was observed in the children after mother-to-child transmission.

6 (per 1,000 days) compared with 0.06-0.51 for mother-to-child transmission.

7 r IPD in pregnancy and strategies to prevent mother-to-child transmission.

8 ad to interventions that reduce the risk for mother-to-child transmission.

9 xposed to nevirapine (NVP) for prevention of mother-to-child transmission.

10 ne ART, the impact of drugs given to prevent mother-to-child transmission, adherence issues and, avai

11 ildren, HIV-exposed neonates at high risk of mother-to-child transmission and children requiring conf

12 ve valuable in protocols aimed at preventing mother-to-child transmission and establishment of infect

13 level (viral load [VL]) is a risk factor for mother-to-child transmission and poor maternal health.

14 months were used to estimate proportions of mother-to-child transmission and transmission risks duri

15 dren exposed to nevirapine for prevention of mother-to-child transmission and with initial viral supp

16 velopment of resistance (the exception being mother-to-child transmission) and various combination dr

17 usly exposed to nevirapine for prevention of mother-to-child transmission, and achieved virological s

18 ations in scalable options for prevention of mother-to-child transmission, and ambitious population-w

19 understanding of HIV, ART, and prevention of mother-to-child transmission, and difficulty managing pr

20 otential for blood-transfusion transmission, mother-to-child transmission, and the development of new

21 cal circumcision, antiretrovirals to prevent mother-to-child transmission, antiretroviral therapy in

22 antiretroviral (ARV) therapy for preventing mother-to-child transmission are indisputable, studies i

23 The overall rate of mother-to-child transmission at 6-8 weeks was 15.3% in 4

24 viral quasispecies found in mothers, the HIV mother-to-child transmission bottleneck favors the trans

25 of opportunistic infections or prevention of mother-to-child transmission did not alter our findings.

26 itor regimens in children with prevention of mother-to-child transmission exposure may reduce risk of

27 In developed countries, the rate of mother-to-child transmission from untreated HIV-infected

28 iency virus (HIV) infection acquired through mother-to-child transmission has important clinical and

29 Critically, fatal cases and mother-to-child transmission have also been described.

30 e living with HIV infection acquired through mother-to-child transmission in New York City.

31 me and how breast-milk virus correlates with mother-to-child transmission is important for establishi

32 after receipt of single-dose NVP to prevent mother-to-child transmission is not well defined.

33 During in utero mother-to-child transmission (IU MTCT), transmitted vira

34 th Africa were enrolled in the prevention of mother-to-child transmission Kesho Bora trial and counse

35 tion antiretroviral therapy reduces rates of mother-to-child transmission (<1% to 2.4% vs. 9% to 2

36 ion women will provide insight into risks of mother to child transmission (MTCT).

37 in late pregnancy for preventing hepatitis B mother-to-child transmission (MTCT) in real-world settin

38 With individual data from seven randomised mother-to-child transmission (MTCT) intervention trials,

39 Mother-to-child transmission (MTCT) of HBV remains an im

40 Ab) are associated with an increased risk of mother-to-child transmission (MTCT) of HCV, HCV nAb tite

41 Despite full immunoprophylaxis, mother-to-child transmission (MTCT) of Hepatitis B Virus

42 Perinatal or mother-to-child transmission (MTCT) of hepatitis B virus

43 Mother-to-child transmission (MTCT) of hepatitis B virus

44 Poor nutrition may be associated with mother-to-child transmission (MTCT) of HIV and other adv

45 breast milk was associated with the risk of mother-to-child transmission (MTCT) of HIV by breastfeed

46 Prevention of mother-to-child transmission (MTCT) of HIV remains a maj

47 ion of sCD14 concentrations with the risk of mother-to-child transmission (MTCT) of HIV, we nested a

48 Mother-to-child transmission (MTCT) of HIV-1 has been as

49 The mechanism of mother-to-child transmission (MTCT) of HIV-1 is not well

50 Mother-to-child transmission (MTCT) of HIV-1 is the majo

51 RNA in breast milk and may therefore reduce mother-to-child transmission (MTCT) of HIV-1 via breast-

52 define humoral immune correlates of risk of mother-to-child transmission (MTCT) of HIV-1, including

53 ngle-dose NVP (SD-NVP) for the prevention of mother-to-child transmission (MTCT) of HIV-1.

54 are well-established factors associated with mother-to-child transmission (MTCT) of HIV; the role of

55 protect against adverse pregnancy outcomes, mother-to-child transmission (MTCT) of human immunodefic

56 Risk factors for mother-to-child transmission (MTCT) of human immunodefic

57 ose nevirapine (sdNVP)-based regimens reduce mother-to-child transmission (MTCT) of human immunodefic

58 nal serum retinol level is a risk factor for mother-to-child transmission (MTCT) of human immunodefic

59 Nvp) prophylaxis is effective for preventing mother-to-child transmission (MTCT) of human immunodefic

60 significant progress in reducing peripartum mother-to-child transmission (MTCT) of human immunodefic

61 Mother-to-child transmission (MTCT) of human immunodefic

62 s a long-standing component of prevention of mother-to-child transmission (MTCT) of human immunodefic

63 cts on infant gut epithelia, and the risk of mother-to-child transmission (MTCT) of human immunodefic

64 ciency virus type 1 (HIV-1) acquired through mother-to-child transmission (MTCT) or failed chemoproph

65 or at least 4 weeks prior to testing, and a mother-to-child transmission (MTCT) rate at 12 months of

66 virus type 1 (HIV-1) treatment outcomes, and mother-to-child transmission (MTCT) risk.

67 ission through the adult oral route is rare, mother-to-child transmission (MTCT) through the neonatal

68 tinues to cause the majority of new cases of mother-to-child transmission (MTCT), and yet there are l

69 tial intervention to prevent postnatal HIV-1 mother-to-child transmission (MTCT).

70 is known about the viral determinants of HIV mother-to-child transmission (MTCT).

71 Mother-to-child-transmission (MTCT) of human immunodefic

72 cific IgG binding that predicted low risk of mother-to-child-transmission (MTCT) was dependent on the

73 whether these boosted responses may prevent mother to child transmission of CMV.

74 The frequency of perinatal mother to child transmission of HIV was increased in wom

75 MQ was associated with an increased risk of mother to child transmission of HIV, which warrants a be

76 rologic suppression, with an overall rate of mother-to-child transmission of 1.1%.

77 Mother-to-child transmission of CD8+ T cell escape varia

78 erogeneity of gag and nef gene sequences and mother-to-child transmission of CD8+ T cell escape varia

79 cell recognition of B57-restricted epitopes, mother-to-child transmission of escape mutations within

80 Mother-to-child transmission of HCV occurs in 3-5% of pr

81 he diagnosis and treatment of HCV infection, mother-to-child transmission of HCV, and possible virus-

82 Although the rate of mother-to-child transmission of hepatitis C virus (HCV)

83 information is available about the timing of mother-to-child transmission of hepatitis C virus (HCV),

84 pite expansion of services for prevention of mother-to-child transmission of HIV (PMTCT), about 700 i

85 s of both antiretroviral prophylaxis against mother-to-child transmission of HIV and antiretroviral t

86 provide a new opportunity to further reduce mother-to-child transmission of HIV and propose that new

87 alaria and for the effect of co-infection on mother-to-child transmission of HIV are areas of major i

88 The mother-to-child transmission of HIV at birth was 8.1% (3

89 Rates of mother-to-child transmission of HIV in Ukraine have decl

90 low-breastfeeding setting with a low risk of mother-to-child transmission of HIV is unclear.

91 beta-carotene (VA/BC) increases the risk of mother-to-child transmission of HIV through breastfeedin

92 rogrammes to reduce child undernutrition and mother-to-child transmission of HIV, and some improvemen

93 le-dose nevirapine (sdNVP) for prevention of mother-to-child transmission of HIV-1 can select nevirap

94 ential clinical importance, target cells for mother-to-child transmission of HIV-1 have not yet been

95 single dose of nevirapine (sdNVP) to prevent mother-to-child transmission of HIV-1 increases the risk

96 l secretions and breast milk and the risk of mother-to-child transmission of HIV-1 were compared amon

97 ipated in a study of sdNVP for prevention of mother-to-child transmission of HIV-1.

98 , low-breastfeeding areas with a low risk of mother-to-child transmission of HIV.

99 ses (e.g., malaria) may increase the risk of mother-to-child transmission of HIV.

100 the use of intrapartum nevirapine to prevent mother-to-child transmission of HIV.

101 s an important opportunity for prevention of mother-to-child transmission of HIV.

102 ve antiretroviral therapy (HAART) to prevent mother-to-child transmission of human immunodeficiency v

103 Intrapartum single-dose nevirapine decreases mother-to-child transmission of human immunodeficiency v

104 To reduce mother-to-child transmission of human immunodeficiency v

105 bed to pregnant women at delivery, to reduce mother-to-child transmission of human immunodeficiency v

106 ive strategies are urgently needed to reduce mother-to-child transmission of human immunodeficiency v

107 (SD) nevirapine (NVP) significantly reduces mother-to-child transmission of human immunodeficiency v

108 use of antiretroviral (ARV) drugs to prevent mother-to-child transmission of human immunodeficiency v

109 ution of neutralizing antibodies in limiting mother-to-child transmission of human immunodeficiency v

110 tum dose of nevirapine for the prevention of mother-to-child transmission of human immunodeficiency v

111 order and delivery route as risk factors for mother-to-child transmission of human immunodeficiency v

112 The rates of mother-to-child transmission of human immunodeficiency v

113 viral therapy (ART) is crucial to preventing mother-to-child transmission of human immunodeficiency v

114 pregnancy are highly effective in preventing mother-to-child transmission of human immunodeficiency v

115 ed to single-dose (sd) NVP for prevention of mother-to-child transmission of human immunodeficiency v

116 oviral (ARV) prophylaxis effectively reduces mother-to-child transmission of human immunodeficiency v

117 retroviral therapy (HAART) for prevention of mother-to-child transmission of human immunodeficiency v

118 Mother-to-child transmission of human immunodeficiency v

119 cornerstone of the regimen for prevention of mother-to-child transmission of human immunodeficiency v

120 nistration of single-dose nevirapine reduces mother-to-child transmission of human immunodeficiency v

121 provirus load in breast milk and the risk of mother-to-child transmission of human T lymphotropic vir

122 d a global initiative for the elimination of mother-to-child transmission of syphilis (congenital syp

123 timing of antenatal interventions to prevent mother-to-child transmission of syphilis and its associa

124 oportion of women who access antenatal care, mother-to-child transmission of syphilis continues to be

125 is the only recommended treatment to prevent mother-to-child transmission of syphilis.

126 l important for achieving the elimination of mother-to-child transmission of syphilis.

127 suggests progress towards the elimination of mother-to-child transmission of syphilis.

128 gle-dose nevirapine (sdNVP) given to prevent mother-to-child-transmission of HIV-1 selects NVP-resist

129 immune response biomarkers in the context of Mother-To-Child-Transmission of HIV-1 viruses.

130 e-limited settings where, in efforts to stem mother-to-child-transmission of HIV-1, transient nonnucl

131 cohort studies of pregnant women on risk for mother-to-child transmission or harms associated with pr

132 ffects of prenatal HIV screening on risk for mother-to-child transmission or maternal or infant clini

133 line HIVDR (P = .04), maternal prevention of mother-to-child transmission (P = .02), and estimated da

134 itted variants, we analyzed 5 viruses from 2 mother-to-child transmission pairs, in which the infant

135 alleles in viral variants obtained from five mother-to-child transmission pairs.

136 nd to have higher adherence to Prevention of Mother to Child Transmission (PMTCT) guidelines, compare

137 ss years of life saved through prevention of mother-to-child transmission (PMTCT) and ART.

138 (HIV-1) RNA in the context of prevention of mother-to-child transmission (PMTCT) interventions is un

139 s, treatment with ART, and the prevention of mother-to-child transmission (pMTCT) of HIV.

140 Programs for the prevention of mother-to-child transmission (PMTCT) of human immunodefi

141 Prevention of mother-to-child transmission (PMTCT) of human immunodefi

142 diatric HIV epidemic by making prevention of mother-to-child transmission (PMTCT) services accessible

143 Such objectives require regimens to prevent mother-to-child transmission (pMTCT) which, while being

144 mong children infected despite prevention of mother-to-child transmission (PMTCT), a substantial prop

145 reexposure prophylaxis (PrEP), prevention of mother-to-child transmission (PMTCT), and postexposure p

146 ssion rates (2.5%), due to HIV prevention of mother-to-child transmission program improvements in Sou

147 for CHTC in Malawi's option B+ prevention of mother-to-child transmission programme: invitation only

148 untries outside the context of prevention of mother-to-child transmission programmes provides an impo

149 The setting of mother-to-child transmission provides an opportunity to

150 well established prevention programmes keep mother-to-child transmission rates at less than 2%.

151 In resource-rich countries, mother-to-child transmission rates of HIV as low as 1% h

152 ction in pregnant women can greatly decrease mother-to-child transmission rates.

153 likely attributable to long-term survival of mother-to-child transmission rather than increases in ri

154 global efforts to scale up the prevention of mother-to-child transmission services and pediatric anti

155 ale-up in antiretroviral-based prevention of mother-to-child transmission services, more than 250 000

156 breastfeeding, indicating a mucosal route of mother-to-child transmission that can be targeted in pre

157 rotease-driven viral replication capacity on mother-to-child transmission, the replication capacities

158 h increased levels of milk HIV-1 and risk of mother-to-child transmission through breastfeeding.

159 sent study, we examined 2 possible routes of mother-to-child transmission, through breast milk and sa

160 the use of antiretroviral therapy to prevent mother-to-child transmission to the possibility of HIV c

161 dren exposed to nevirapine for prevention of mother-to-child transmission who were aged 3 years or ol